ArticleJournal of translational medicine2025
KBTBD11 suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- ENO1 as a Central Regulator Linking Metabolic Reprogramming to Tumor Plasticity.International journal of molecular sciences · 2026Review
- CRISPR Screening in Hepatocellular Carcinoma: From Tumor Progression to Immune Evasion and Therapeutic Resistance.International journal of molecular sciences · 2026Review
- γ-terpinene inhibits the progression of hepatocellular carcinoma by regulating the PTEN/PI3K/Akt signaling pathway mediated glycolysis.Scientific reports · 2026Article
- Molecular regulatory network of glycolytic reprogramming in hepatocellular carcinoma and its clinical implications.Biological procedures online · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Enhanced aerobic glycolysis is a hallmark of HCC progression, yet the upstream regulatory mechanisms remain incompletely understood.
methodsAn in vivo genome-wide CRISPR-Cas9 screen in an orthotopic HCC model was used to identify metabolic regulators. Functional assays including extracellular flux analysis, ATP and lactate quantification, ROS detection, apoptosis assays, and 3D spheroid culture were performed to evaluate the effects of KBTBD11. Protein interactions were assessed by co-immunoprecipitation, ubiquitination assays, and truncation mutant analysis. Spatial interactions and subcellular localization of KBTBD11 and ENO1 were further validated by proximity ligation assay (PLA) and immunofluorescence staining.
resultsKBTBD11 was frequently downregulated in HCC and associated with favorable prognosis. Overexpression of KBTBD11 suppressed glycolytic activity, reduced ATP and lactate levels, elevated ROS accumulation, and promoted apoptosis. Mechanistically, KBTBD11 interacted with ENO1 and facilitated its proteasomal degradation via a ubiquitin-dependent pathway. Deletion of either the BTB or Kelch domain of KBTBD11 impaired its ability to bind ENO1. Rescue experiments using ENO1 re-expression or pharmacological inhibition by ENOblock confirmed that the metabolic and phenotypic effects of KBTBD11 were ENO1-dependent.
conclusionsThese findings identify KBTBD11 as a negative regulator of ENO1-mediated glycolysis in HCC. By promoting ENO1 degradation, KBTBD11 links ubiquitin signaling to metabolic control and tumor suppression, highlighting a potential therapeutic target for metabolically active liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.